Elite in Smoldering Multiple Myeloma

Dr. Omar Nadeem

Oncology
Brigham and Women’s Hospital
Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
450 Brookline Avenue, 
Boston, MA 
Offers Telehealth
17 Years of Experience
Elite in Smoldering Multiple Myeloma
Brigham and Women’s Hospital
Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
450 Brookline Avenue, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Omar Nadeem is an Oncologist in Boston, Massachusetts. Dr. Nadeem has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Smoldering Multiple Myeloma, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles and participated in 2 clinical trials in the study of Smoldering Multiple Myeloma.

Graduate Institution
Ross University School Of Medicine, 2005 - 2009, 2009
Residency
Dartmouth Hitchcock Medical Center, 2009 - 2012
Specialties
Oncology
Licenses
Internal Medicine in MA
Fellowships
Brown University, 2012 - 2015
Rhode Island Hospital/Lifespan, 2012 - 2015
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
450 Brookline Avenue, Boston, MA 02115
Call: 617-632-4852

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Other, Drug
Study Drug: Metformin XR
Study Phase: Phase 2
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drugs: Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone
Study Phase: Phase 2
B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma
B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: April 25, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone
Study Phase: Phase 2
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 02, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Study Phase: Phase 1/Phase 2
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: September 21, 2023
Intervention Type: Genetic, Drug
Study Drugs: Fludarabine, Cyclophosphamide
Study Phase: Phase 1
View 6 Less Clinical Trials

79 Total Publications

Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Journal: Expert opinion on emerging drugs
Published: October 30, 2025
View All 79 Publications
Similar Doctors
Jacob P. Laubach
Elite in Smoldering Multiple Myeloma
Dr. Jacob P. Laubach
Oncology | Hematology
Elite in Smoldering Multiple Myeloma
Dr. Jacob P. Laubach
Oncology | Hematology

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center

450 Brookline Avenue, 
Boston, MA 
 (0.1 miles away)
617-632-4218
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jacob Laubach is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Laubach is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

Nikhil C. Munshi
Elite in Smoldering Multiple Myeloma
Dr. Nikhil C. Munshi
Oncology
Elite in Smoldering Multiple Myeloma
Dr. Nikhil C. Munshi
Oncology

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center

450 Brookline Avenue, 
Boston, MA 
 (0.1 miles away)
617-632-5607
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nikhil Munshi is an Oncologist in Boston, Massachusetts. Dr. Munshi is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Castleman Disease, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration.

Paul G. Richardson
Elite in Smoldering Multiple Myeloma
Dr. Paul G. Richardson
Hematology Oncology | Oncology | Hematology
Elite in Smoldering Multiple Myeloma
Dr. Paul G. Richardson
Hematology Oncology | Oncology | Hematology

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center

450 Brookline Avenue, 
Boston, MA 
 (0.1 miles away)
617-632-2104
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Richardson is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Richardson is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft.

VIEW MORE SMOLDERING MULTIPLE MYELOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nadeem's expertise for a condition
ConditionClose
  • Elite
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
    Dr. Nadeem is
    Elite
    . Learn about Monoclonal Gammopathy of Undetermined Significance (MGUS).
    See more Monoclonal Gammopathy of Undetermined Significance (MGUS) experts
  • Multiple Myeloma
    Dr. Nadeem is
    Elite
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Smoldering Multiple Myeloma
    Dr. Nadeem is
    Elite
    . Learn about Smoldering Multiple Myeloma.
    See more Smoldering Multiple Myeloma experts
  • Distinguished
  • Adult Immune Thrombocytopenia
    Dr. Nadeem is
    Distinguished
    . Learn about Adult Immune Thrombocytopenia.
    See more Adult Immune Thrombocytopenia experts
  • Chronic Lymphocytic Leukemia (CLL)
    Dr. Nadeem is
    Distinguished
    . Learn about Chronic Lymphocytic Leukemia (CLL).
    See more Chronic Lymphocytic Leukemia (CLL) experts
  • Hemangioma Thrombocytopenia Syndrome
    Dr. Nadeem is
    Distinguished
    . Learn about Hemangioma Thrombocytopenia Syndrome.
    See more Hemangioma Thrombocytopenia Syndrome experts
  • Myelodysplastic Syndrome (MDS)
    Dr. Nadeem is
    Distinguished
    . Learn about Myelodysplastic Syndrome (MDS).
    See more Myelodysplastic Syndrome (MDS) experts
  • Non-Hodgkin Lymphoma
    Dr. Nadeem is
    Distinguished
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • Relapsed Refractory Multiple Myeloma (RRMM)
    Dr. Nadeem is
    Distinguished
    . Learn about Relapsed Refractory Multiple Myeloma (RRMM).
    See more Relapsed Refractory Multiple Myeloma (RRMM) experts
View All 8 Distinguished Conditions
  • Advanced
  • Agranulocytosis
    Dr. Nadeem is
    Advanced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anemia
    Dr. Nadeem is
    Advanced
    . Learn about Anemia.
    See more Anemia experts
  • Chronic B-Cell Leukemia (CBCL)
    Dr. Nadeem is
    Advanced
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
  • Essential Thrombocythemia
    Dr. Nadeem is
    Advanced
    . Learn about Essential Thrombocythemia.
    See more Essential Thrombocythemia experts
  • Familial Colorectal Cancer
    Dr. Nadeem is
    Advanced
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Follicular Lymphoma
    Dr. Nadeem is
    Advanced
    . Learn about Follicular Lymphoma.
    See more Follicular Lymphoma experts
View All 12 Advanced Conditions
  • Experienced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Nadeem is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Nadeem is
    Experienced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Nadeem is
    Experienced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Arterial Embolism
    Dr. Nadeem is
    Experienced
    . Learn about Arterial Embolism.
    See more Arterial Embolism experts
  • B-Cell Lymphoma
    Dr. Nadeem is
    Experienced
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Bone Marrow Aspiration
    Dr. Nadeem is
    Experienced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.